Syros Pharmaceuticals, Inc. NASDAQ:SYRS

Founder-led company

Syros Pharmaceuticals stock price today

$0.006
-0.20
-97.37%
Financial Health
0
1
2
3
4
5
6
7
8
9

Syros Pharmaceuticals stock price monthly change

-96.52%
month

Syros Pharmaceuticals stock price quarterly change

-96.52%
quarter

Syros Pharmaceuticals stock price yearly change

-97.14%
year

Syros Pharmaceuticals key metrics

Market Cap
5.41M
Enterprise value
N/A
P/E
-0.37
EV/Sales
-4.49
EV/EBITDA
0.76
Price/Sales
0.61
Price/Book
0.09
PEG ratio
N/A
EPS
-5.00
Revenue
N/A
EBITDA
-123.17M
Income
-144.49M
Revenue Q/Q
-100%
Revenue Y/Y
-8.79%
Profit margin
-441.74%
Oper. margin
-667.78%
Gross margin
30.84%
EBIT margin
-667.78%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Syros Pharmaceuticals stock price history

Syros Pharmaceuticals stock forecast

Syros Pharmaceuticals financial statements

Average Price Target
Last Year

$5

Potential upside: 90809.09%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS): Profit margin
Jun 2023 2.83M -36.25M -1279.84%
Sep 2023 3.76M -40.14M -1067.07%
Dec 2023 386K -64.38M -16679.79%
Mar 2024 0 -3.70M
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS): Debt to assets
Jun 2023 180982000 107.74M 59.53%
Sep 2023 147795000 111.49M 75.44%
Dec 2023 168174000 151.51M 90.09%
Mar 2024 134728000 119.67M 88.82%
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS): Cash Flow
Jun 2023 -22.38M 32.92M 140K
Sep 2023 -31.85M 28.64M -5K
Dec 2023 -18.56M 1.52M 43.38M
Mar 2024 -31.09M -24.64M -265K

Syros Pharmaceuticals alternative data

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS): Employee count
Aug 2023 117
Sep 2023 117
Oct 2023 117
Nov 2023 117
Dec 2023 117
Jan 2024 117
Feb 2024 117
Mar 2024 117
Apr 2024 117
May 2024 68
Jun 2024 68
Jul 2024 68

Syros Pharmaceuticals other data

100.00% +43.60%
of SYRS is owned by hedge funds
9.27M +5.71M
shares is hold by hedge funds

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS): Insider trades (number of shares)
Period Buy Sel
Apr 2024 0 10601
Jun 2024 0 34837
Sep 2024 200000 0
Nov 2024 0 502202
Dec 2024 0 37070
Transaction Date Insider Security Shares Price per share Total value Source
Sale
SIMONIAN NANCY A director Common Stock 37,070 $0.27 $10,009
Sale
SIMONIAN NANCY A director Common Stock 134,713 $0.27 $35,699
Sale
QUIRK GERALD E officer: Chief Legal & Complian..
Common Stock 46,657 $0.22 $10,311
Sale
STEPHENS KRISTIN officer: Chief Development Offi..
Common Stock 36,133 $0.22 $7,949
Sale
ROTH DAVID officer: Chief Me.. Common Stock 12,099 $0.2 $2,384
Sale
CHEE CONLEY director, officer: President & ..
Common Stock 134,797 $0.2 $26,959
Sale
HAAS JASON officer: Chief Financial Officer
Common Stock 137,803 $0.21 $28,939
Option
SIMONIAN NANCY A director Common Stock 40,125 N/A N/A
Option
SIMONIAN NANCY A director Restricted Stock Units 40,125 N/A N/A
Option
ROTH DAVID officer: Chief Me.. Common Stock 18,875 N/A N/A
Patent
Grant
Filling date: 16 Jan 2019 Issue date: 26 Apr 2022
Grant
Filling date: 8 Sep 2017 Issue date: 15 Mar 2022
Application
Filling date: 25 Aug 2021 Issue date: 17 Feb 2022
Application
Filling date: 16 Jan 2019 Issue date: 6 Jan 2022
Application
Filling date: 1 Nov 2019 Issue date: 30 Dec 2021
Application
Filling date: 1 Nov 2019 Issue date: 30 Dec 2021
Application
Filling date: 16 Jan 2019 Issue date: 9 Dec 2021
Grant
Filling date: 3 Jun 2016 Issue date: 21 Sep 2021
Application
Filling date: 1 Jun 2021 Issue date: 16 Sep 2021
Grant
Filling date: 3 Apr 2018 Issue date: 10 Aug 2021
Thursday, 14 November 2024
zacks.com
Wednesday, 13 November 2024
benzinga.com
Tuesday, 12 November 2024
businesswire.com
Monday, 4 November 2024
accesswire.com
Sunday, 3 November 2024
accesswire.com
Saturday, 2 November 2024
accesswire.com
Thursday, 31 October 2024
seekingalpha.com
businesswire.com
Sunday, 27 October 2024
accesswire.com
Saturday, 26 October 2024
accesswire.com
Thursday, 24 October 2024
businesswire.com
Wednesday, 23 October 2024
accesswire.com
Monday, 21 October 2024
accesswire.com
Sunday, 20 October 2024
accesswire.com
Saturday, 19 October 2024
accesswire.com
Friday, 18 October 2024
accesswire.com
Thursday, 17 October 2024
accesswire.com
Monday, 14 October 2024
accesswire.com
Sunday, 13 October 2024
accesswire.com
Saturday, 12 October 2024
accesswire.com
Friday, 11 October 2024
accesswire.com
Thursday, 10 October 2024
accesswire.com
Wednesday, 9 October 2024
accesswire.com
Tuesday, 8 October 2024
accesswire.com
Monday, 7 October 2024
accesswire.com
Sunday, 6 October 2024
accesswire.com
Saturday, 5 October 2024
accesswire.com
Friday, 4 October 2024
accesswire.com
Thursday, 3 October 2024
accesswire.com
Wednesday, 2 October 2024
accesswire.com
  • What's the price of Syros Pharmaceuticals stock today?

    One share of Syros Pharmaceuticals stock can currently be purchased for approximately $0.01.

  • When is Syros Pharmaceuticals's next earnings date?

    Unfortunately, Syros Pharmaceuticals's (SYRS) next earnings date is currently unknown.

  • Does Syros Pharmaceuticals pay dividends?

    No, Syros Pharmaceuticals does not pay dividends.

  • How much money does Syros Pharmaceuticals make?

    Syros Pharmaceuticals has a market capitalization of 5.41M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 33.23% to 9.94M US dollars.

  • What is Syros Pharmaceuticals's stock symbol?

    Syros Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "SYRS".

  • What is Syros Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Syros Pharmaceuticals?

    Shares of Syros Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Syros Pharmaceuticals's key executives?

    Syros Pharmaceuticals's management team includes the following people:

    • Dr. Nancy A. Simonian M.D. Pres, Chief Executive Officer & Director(age: 64, pay: $1,030,000)
    • Dr. David A. Roth Chief Medical Officer(age: 62, pay: $713,030)
    • Dr. Eric R. Olson Chief Scientific Officer(age: 67, pay: $696,420)
    • Dr. Richard A. Young Ph.D. Scientific Founder, Member of Scientific Advisory Board & Director(age: 71, pay: $165,000)
  • Is Syros Pharmaceuticals founder-led company?

    Yes, Syros Pharmaceuticals is a company led by its founder Dr. Richard A. Young Ph.D..

  • How many employees does Syros Pharmaceuticals have?

    As Jul 2024, Syros Pharmaceuticals employs 68 workers, which is 42% less then previous quarter.

  • When Syros Pharmaceuticals went public?

    Syros Pharmaceuticals, Inc. is publicly traded company for more then 9 years since IPO on 30 Jun 2016.

  • What is Syros Pharmaceuticals's official website?

    The official website for Syros Pharmaceuticals is syros.com.

  • Where are Syros Pharmaceuticals's headquarters?

    Syros Pharmaceuticals is headquartered at 35 CambridgePark Drive, Cambridge, MA.

  • How can i contact Syros Pharmaceuticals?

    Syros Pharmaceuticals's mailing address is 35 CambridgePark Drive, Cambridge, MA and company can be reached via phone at +61 77441340.

  • What is Syros Pharmaceuticals stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for Syros Pharmaceuticals in the last 12 months, the avarage price target is $5. The average price target represents a 90809.09% change from the last price of $0.01.

Syros Pharmaceuticals company profile:

Syros Pharmaceuticals, Inc.

syros.com
Exchange:

NASDAQ

Full time employees:

68

Industry:

Biotechnology

Sector:

Healthcare

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

35 CambridgePark Drive
Cambridge, MA 02140

CIK: 0001556263
ISIN: US87184Q2066
CUSIP: 87184Q107